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HAART. Race et al recognized this on initiation of a protease
inhibitor, indinavir, in patients with advanced HIV-1 disease
[3]. A retrospective studyconducted on 52 patientswithmyco-
bacterial lymphadenitis in HIV showed 12 patients developed
the infection within 12weeks of initiating combination anti-
retroviral therapy. The clinical presentation, which may vary,
was in these cases of localized disease andwas associatedwith a
relatively high CD4 count. All patients showed a good immu-
nological and virological response toHAART [4].
A further analysis identi¢ed ¢ve patients who developed
mycobacterial lymphadenitis within 8weeks of initiating
HAART. All patients had fever, weakness and splenomegaly.
Four of the ¢ve patients were anemic with Hb<10 g/dL and
demonstrated lymphadenopathy. This was cervical in three,
submandibular in two, mediastinal in three and preauricular
in one [5]. Interestingly, our patient presented with a primary
lung lesion (Figure 1).We are not aware of any other literature
describing cavitatory lung lesions, due to localized MAC
infection, relating to HAART therapy inHIVinfection.
MAC infections may re£ect restoration of pathogen-speci-
¢c immune responses rather than reactivation of the initiating
infection. Partial immune reconstitution, as demonstrated by
an increase in the CD4 counts on anti-retroviral therapy is
likely to be responsible for the localized MAC infection.This
reconstitution may lead to an unmasking of subclinical infec-
tion and an enhanced immune response to mycobacterial anti-
gens. There is evidence to show that immune reconstitution
due to HAARToccurs in two stages and the initial CD4 lym-
phocyte proliferation is primarly of the memory subsets [6^8].
Thus this marked memoryT-cell-mediated and antigen-spe-
ci¢c in£ammatory reaction may then lead to tissue suppura-
tion and granuloma formation, the hallmarks of
mycobacterial disease.
The occurence and severity of illness in our patient with
localized but untreated MAC infection after the start of
HAART suggests that patients with advanced HIV disease
should be assessed for active mycobacterial infection before
the initiation of such therapy. It is also important to consider
that dual opportunistic infections may occur in advanced dis-
ease as our patient demonstrated. Therefore, patients with
severe immune dysfunction should be monitored very care-
fully, in particular during the ¢rst weeks after initiating of
HAART. Indeed, it may be important in the ¢rst few months
of HAART to maintain patients on prophylaxis for opportu-
nistic infections.
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Endocarditis due to Gemella haemolysans in a patient with
hemochromatosis
Gemella haemolysans is a facultative anaerobic Gram-positive
coccus that can be a commensal of the upper respiratory tract
and oral cavity of humans.The clinical spectrum of infections
produced by this microorganism includes endocarditis, septi-
cemia and meningitis.We report a case of endocarditis due to
G. haemolysans in a patients with hemochromatosis.
A 77-year-old manwith a long history of hemochromatosis
with chronic liver disease and arterial hypertension was
admitted to hospital because of malaise, anorexia, weight loss
and progressive dyspnea over the previous 4months. On
admission he was afebrile and the physical examination
revealed a grade 2 diastolic ejection murmur in the left sternal
border and hepatomegaly. Laboratory studies disclosed the
following data: leukocyte count 12 000/mm3 (80% neutro-
phils, 17% lymphocytes), hematocrit 48%, erythrocyte sedi-
mentation rate of 54mm/h, iron 200 mg/dL, ferritin 2277U
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mg/L, AST 64U/mL and ALT 57U/mL. Radiographs of the
chest were normal. Echocardiography revealed a vegetation
on the aortic valve with moderate valvular insu¤ciency. G.
haemolysans was isolated in the three blood cultures taken on
admission. The identi¢cation was performed on the basis of
Gram stain, catalase activity and biochemical characteristics
(API 20 STREP, BioMe© rieux, France).The isolate was suscep-
tible to penicillin (MIC: 0.06mg/L). The patient was treated
with penicillin G (24 MU IV daily, divided in six doses) and
tobramycin (100mg twice a day IV) for 2 weeks whereupon
he showed improvement of his clinical status as well as
sterilization of the blood cultures. In a follow-up visit 30 days
after discharge, the echocardiogram did not show any vegeta-
tion.
G. haemolysans was ¢rst described in 1938 by Thjo« tta and
Bo« e [1] as Neisseria haemolysans but was reclassi¢ed into a new
genus, Gemella, following demonstration of biochemical dif-
ferences with other Neisseria. This species is easily decolorized
during Gram staining andmay therefore appear as Gram-vari-
able or even Gram-negative. It can be misidenti¢ed as a viri-
dans streptococcus or remain unidenti¢ed. An accurate
identi¢cation can be made with commercial biochemical tests
such as theAPI 20 STREP system.
To the best of our knowledge, 15 cases of endocarditis due
toG. hemolysans have been reported so far [2^14].The available
information is shown inTable 1. Mean age was 53.2 years and
ranged from 20 to 77 years. Of 16 patients, only two were
women (12.5%). All but two cases occured in patients with
underlying mitral or aortic valve disease (including prosthetic
valves) and/or poor dentition or dental manipulation [5,10].
Infected valves were aortic and mitral, both of them with the
same percentage (50%). The outcome was completely favor-
able after antibiotic treatment, although some patients needed
valve replacement [2^4,9,10,12,13]. In our patient, aortic valve
insu¤ciency was the only risk factor identi¢ed for endocardi-
tis but, interestingly, he had hemochromatosis.The association
of G. haemolysans with hemochromatosis has not been
reported to date and in this case probably represents a casual
relationship between two uncommon conditions. However,
the increased availability of iron in patients could have
enhanced the virulence of G. haemolysans as has been demon-
strated with other bacterial species such asYersinia spp.,Vibrio
Table 1 Summary of patients with reported cases of G. haemolysans endocarditis
Case/Reference Age/Sex
Underlying conditions or
source of infection
Infected
valve Treatment Outcome
1/1 62/M Dental manipulation Mi Cefamandole, gentamicin,
benzylpenicillin, amoxicillin
Survived
2/1 48/M Poor dentition, respiratory viral
syndrome
Ao Benzylpenicillin, gentamicin Survived
3/1 56/M Mi insuf®ciency, dental manipulation Mi Benzylpenicillin, gentamicin Survived
4/2 68/M Ao insuf®ciency Ao Benzylpenicillin, streptomycin Survived
5/3 47/M Prosthetic aortic valve, periodontal
disease
Ao Erythromycin, rifampin Survived
6/4 62/F None Mi Benzylpenicillin, tobramycin,
clindamycin
Survived
7/5 74/M Mi prolapsed Mi Benzylpenicillin, gentamicin,
amoxicillin
Survived
8/6 42/M Ao insuf®ciency, wound Ao Vancomycin, fusidic acid, amoxicillin,
gentamicin
Survived
9/7 71/M Colonic carcinoma Mi Amoxicillin, clavulanic acid, gentamicin Survived
10/8 53/F Mi regurgitation Mi Benzylpenicillin, gentamicin Survived
11/9 20/M None Ao Benzylpenicillin, gentamicin Survived
12/10 34/M Prosthetic valve, endocarditis, dental
sepsis
Ao Cefuroxime, tobramycin, cipro¯oxacin,
erythromycin
Survived
13/11 48/M Prosthetic Ao and Mi valves Mi Benzylpenicillin, gentamicin Survived
14/12 63/M Chronic obstructive bronchitis, poor
dentition
Mi Amoxicillin, amikacin Survived
15/13 26/M Down syndrome, Ao insuf®ciency,
ventricular septal defect
Ao Benzylpenicillin, gentamicin Survived
Present report 77/M Ao insuf®ciency, hemochromatosis Ao Benzylpenicillin, tobramycin Survived
Note: Sex (M,Male; F, Female);Valves (Ao, Aortic valve;Mi,Mitral valve).
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spp., and some mycobacteria among others [15]. In summary,
our case suggests that hemochromatosis may be a risk factor
for endocarditis due toG. haemolysans.
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Unusual high-performance liquid chromatography pro®le of
a strain of Mycobacterium avium
Mycobacterium avium complex (MAC) is the most frequently
detected non-tuberculous mycobacterium, not only in AIDS
patients, where it is responsible for disseminated and localized
infections, but also in non-immunocompromised subjects.
Among the latter, it is frequently responsible for pulmonary
disease in elderly people with various predisposing conditions,
and for cervical lymphadenitis in the children [1].
Several di¡erent approaches can be applied for the identi¢-
cation of MAC: conventional tests reveal well-de¢ned bio-
chemical and cultural features; highly speci¢c commercial
DNA probes (AccuProbe, USA) react with a species-speci¢c
16S rRNA stretch; and ¢nally, high-performance liquid chro-
matography (HPLC) of cell wall mycolic acids provides an
easily recognizable pattern characterized by three clusters of
peaks (Figure1b).
Herein, we report the characterization of two strains iso-
lated from sputum collected at 5-month intervals from the
same immunocompetent elderly subject. Both isolates had the
phenotypic features of MAC, and both reacted with AccuP-
robeM. avium, but not with AccuProbeM. intracellulare.
Figure 1 Mycolic acid patterns obtained by HPLC: (a) pro®le of
the ®rst strain (atypical); (b) pro®le of the second strain (MAC-
typical). LMWIS and HMWIS are low and high molecular
weight internal standards, respectively.
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